Halozyme Therapeutics (HALO) Share-based Compensation (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Share-based Compensation data on file, last reported at $16.6 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $16.6 million, up 55.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $57.5 million (up 30.2% YoY), and the FY2025 annual result was $51.6 million, up 18.85% from the prior year.
• Share-based Compensation steadied at $16.6 million in Q1 2026 per HALO's latest filing, from $16.6 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $16.6 million in Q1 2026 and troughed at $4.7 million in Q1 2022.
• A 5-year average of $10.2 million and a median of $9.7 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation retreated 3.68% in 2022, then surged 70.75% in 2023.
• A 5-year view of Share-based Compensation shows it stood at $7.2 million in 2022, then soared by 33.79% to $9.7 million in 2023, then gained by 18.61% to $11.5 million in 2024, then soared by 44.57% to $16.6 million in 2025, then rose by 0.4% to $16.6 million in 2026.
• Business Quant data shows HALO's Share-based Compensation at $16.6 million in Q1 2026, $16.6 million in Q4 2025, and $12.2 million in Q3 2025.